ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pharma Giants Team Up On Diabetes Candidate

by Rick Mullin
May 6, 2013 | APPEARED IN VOLUME 91, ISSUE 18

Merck & Co. and Pfizer are joining to develop Pfizer’s ertugliflozin, an investigational sodium glucose cotransporter inhibitor for type 2 diabetes that will enter Phase III clinical trials later this year. Under the agreement, the two companies will develop the small-molecule drug alone and in combination with metformin, a generic diabetes drug, and Merck’s Januvia (sitagliptin). Pfizer has received an up-front payment of $60 million and is eligible for milestone payments. Merck and Pfizer will share potential revenue and development costs on a 60:40 basis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment